(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
2.83% $ 13.82
Live Chart Being Loaded With Signals
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne...
Stats | |
---|---|
Объем за сегодня | 4 552.00 |
Средний объем | 12 476.00 |
Рыночная капитализация | 33.08M |
EPS | $-0.000220 ( 2023-06-29 ) |
Last Dividend | $0.195 ( 2023-12-14 ) |
Next Dividend | $0 ( N/A ) |
P/E | -16.01 |
ATR14 | $0.238 (1.72%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-05 | Rosenwald Lindsay A Md | Buy | 50 000 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lu Lucy | Buy | 3 333 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lorenz Kevin | Buy | 3 333 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lobell J Jay | Buy | 6 666 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Klein Dov | Buy | 6 666 | COMMON STOCK, PAR VALUE $0.001 |
INSIDER POWER |
---|
100.00 |
Last 51 transactions |
Buy: 13 110 352 | Sell: 133 334 |
Fortress Biotech Inc. Корреляция
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Fortress Biotech Inc. Финансовые показатели
Annual | 2023 |
Выручка: | $84.51M |
Валовая прибыль: | $55.62M (65.82 %) |
EPS: | $-7.48 |
FY | 2023 |
Выручка: | $84.51M |
Валовая прибыль: | $55.62M (65.82 %) |
EPS: | $-7.48 |
FY | 2022 |
Выручка: | $75.74M |
Валовая прибыль: | $44.97M (59.37 %) |
EPS: | $-36.10 |
FY | 2021 |
Выручка: | $68.79M |
Валовая прибыль: | $36.71M (53.36 %) |
EPS: | $-0.980 |
Financial Reports:
No articles found.
Fortress Biotech Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.390 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.586 | 2018-03-14 |
Last Dividend | $0.195 | 2023-12-14 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-31 | |
Next Payout Date | N/A | |
# dividends | 51 | -- |
Total Paid Out | $13.86 | -- |
Avg. Dividend % Per Year | 7.56% | -- |
Score | 5.87 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 5.00 | |
Div. Directional Score | 1.121 | -- |
Year | Amount | Yield |
---|---|---|
2018 | $2.34 | 10.60% |
2019 | $2.34 | 14.50% |
2020 | $2.34 | 11.40% |
2021 | $2.34 | 12.10% |
2022 | $2.15 | 8.20% |
2023 | $2.34 | 13.30% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.724 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.365 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.56 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | -0.143 | -1.000 | -1.432 | 1.432 | [0 - 1] |
currentRatioTTM | 1.378 | 0.800 | 8.11 | 6.49 | [1 - 3] |
quickRatioTTM | 1.134 | 0.800 | 8.03 | 6.43 | [0.8 - 2.5] |
cashRatioTTM | 0.953 | 1.500 | 5.82 | 8.72 | [0.2 - 2] |
debtRatioTTM | 0.420 | -1.500 | 3.01 | -4.51 | [0 - 0.6] |
interestCoverageTTM | -11.92 | 1.000 | -5.53 | -5.53 | [3 - 30] |
operatingCashFlowPerShareTTM | -8.50 | 2.00 | -2.83 | -5.66 | [0 - 30] |
freeCashFlowPerShareTTM | -8.57 | 2.00 | -4.28 | -8.57 | [0 - 20] |
debtEquityRatioTTM | 3.12 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.680 | 1.000 | 1.999 | 1.999 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1.681 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1.824 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.504 | 0.800 | 9.97 | 7.98 | [0.5 - 2] |
Total Score | -2.76 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.424 | 1.000 | -0.144 | 0 | [1 - 100] |
returnOnEquityTTM | -2.56 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -8.57 | 2.00 | -2.86 | -8.57 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -8.50 | 2.00 | -2.83 | -5.66 | [0 - 30] |
payoutRatioTTM | -0.143 | 1.500 | -1.432 | 1.432 | [0 - 1] |
pegRatioTTM | -0.00785 | 1.500 | -3.39 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -1.517 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -3.87 |
Fortress Biotech Inc.
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа